Lung cancer is the leading cause of cancer death in the United States in all ethnic and racial groups. The overall death rate from lung cancer is higher in black patients than in white patients.
L ung cancer remains the leading cause of death from cancer in the United States. 1 Black populations have the highest lung cancer mortality rate of any racial or ethnic group in the United States. 2 The average annual ageadjusted incidence is 65.0 and 58.8 per 100 000 in black patients and white patients, respectively. 2 Many factors may contribute to the disparities in both incidence and outcome including differences in access to health care, smoking behavior, and other socioeconomic variables. [3] [4] [5] However, these known risk factors do not fully explain the differences in the incidence and outcome between these 2 populations. [6] [7] [8] Acquired alterations to the cancer genome-including somatic single-nucleotide variants, insertions and deletions (indels), copy number variations (CNVs), and structural rearrangements-contribute to tumorigenesis by activating pathways involved in cell growth and proliferation, resistance to apoptosis, and immune cell invasion. 9 Alterations in receptor tyrosine kinases (RTKs) such as EGFR, ALK, RET, and ROS1 are clinically important as they confer sensitivity to kinase inhibitors in lung adenocarcinomas. 10, 11 Recent studies [12] [13] [14] led by our group and The Cancer Genome Atlas (TCGA) have performed comprehensive molecular characterization of lung tumors to identify other potentially targetable alterations. We have shown that the frequency of acquired alterations in lung cancer driver genes are largely distinct between the 2 largest subclasses of non-small-cell lung cancer (NSCLC), lung adenocarcinoma, and lung squamous cell carcinoma.
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In addition to histology, the frequency of acquired alterations in lung tumors can vary across sex, smoking status, and ancestral populations. 10 For example, EGFR kinase domain mutations occur at a significantly higher frequency in lung adenocarcinomas from women compared with men, never-smokers compared with smokers, and East Asian populations compared with nonAsian populations. 10, 16, 17 The higher rates of EGFR mutations in these populations have resulted in a corresponding higher rate of patients with clinical response to EGFR inhibitors. [18] [19] [20] Studies examining mutational profiles of EGFR in tumors from patients with black ancestry have been less conclusive. Some studies have reported significantly lower frequencies of EGFR mutations in black patients compared with whites, 21-24 while other studies did not observe any association of EGFR mutation status with ancestry or self-reported race. [25] [26] [27] [28] The interpretation of these findings have been limited by the presence of confounding factors such as sex and smoking status or by the fact that cohorts were pooled together from different clinical settings across different institutions. Moving beyond EGFR, a more recent study 25 examining a panel of known driver mutations across several hundred NSCLC samples found a lower overall frequency of mutations in any gene in tumors from black patients compared with white patients. 25 However, no studies have been performed that comprehensively characterize genomic alterations across hundreds of well-known cancer genes in a large number of tumors from both black and white populations. To understand the relationship between tumoral genomic alterations and black ancestry, we profiled the exome sequences of 504 cancer genes in 509 lung cancers from black patients and white patients. These tumors were collected from patients in the same clinical setting and were well matched for clinical covariates. We did not identify enrichment of mutations or copy number changes in either population. These results suggest that targeted therapies and biomarker-driven clinical trials should significantly benefit patients in both groups.
Methods

Sample Collection
Formalin-fixed paraffin-embedded (FFPE) lung tumor specimens were collected from black and white patients from Baptist Cancer Center in Memphis, Tennessee. All specimens were obtained from patients with approval from the relevant institutional review boards. Lung cancer cases from January 2004 to December 2012 were identified from a search of pathology department records across 3 health care systems (Baptist Memorial Health Care, Methodist-LeBonheur Healthcare, and St Francis Healthcare) in metropolitan Memphis. Race was categorized by patient self-identification. From each institution, specimens from black patients were paired with specimens from white patients by matching for histology, sex, and age.
Sequencing and Analysis
In total, 607 tumors underwent DNA isolation and sequencing of 504 cancer-related genes using the OncoPanel platform 29 (eMethods in Supplement 1 and eTable 1 in Supplement 2). Overall, 550 libraries with sufficient material were submitted for sequencing. Thirty tumors were excluded for failing sequencing quality control (eMethods in Supplement 1), and an additional 11 tumors were excluded due to insufficient clinical annotation, leaving a total of 509 tumors for analysis. Data were aligned and processed as previously described (eMethods in Supplement 1). [30] [31] [32] [33] Principal component analysis (PCA) 34, 35 and other statistical analyses are described in eMethods in Supplement 1. Because we did not have paired normal tissue for these patients, we excluded variants found in exomes of noncancer tissue using the Exome Aggregation Consortium database (eFigure 1 in Supplement 1).
2). This included 319 adenocarcinomas, 142 squamous cell carcinomas, 47 NSCLC of other histology, and 1 small-cell carcinoma. Twenty-nine samples were obtained from a biopsy of a nonlung site for a putative lung cancer metastasis. The majority of tumors were stage I (n = 305) or stage II (n = 98). We performed secondary pathological review for 380 lung cancers (eMethods in Supplement 1) and confirmed histological classification in 223 of 247 lung adenocarcinomas (90%) and 80 of 97 squamous cell carcinomas (82%).
Association of Self-reported Race With Germline Variation
Previous studies have noted that self-reported clinical variables such as race and sex are not always congruent with underlying biological ancestry or sex as defined by genetic variation and structure. 36 To examine the relationship between self-reported race and biological ancestry, we performed PCA on single-nucleotide variants (SNVs) likely to be inherited and not somatically acquired (eMethods and eFigure 1 in Supplement 1). Principal component 1 (PC1) was strongly associated with self-reported race (Wilcoxon rank-sum test
)( Figure 1 ). Two SNV profiles from reported white patients clustered with the samples from black patients, and 6 SNV profiles from reported black patients clustered with the white patient samples. Additionally, 3 samples were outliers along PC2. These 11 samples were excluded from all further analyses examining the association between ancestry and genomic alterations.
Mutational Signatures
Various exogenous exposures or endogenous biological processes can contribute to the overall mutational load observed in lung tumors. We identified 4 mutational signatures present in the cohort 37 (eMethods in Supplement 1). These signatures were strongly correlated with previously characterized signatures of smoking (designated as SI4), aberrant APOBEC (apolipoprotein B messenger RNA editing enzyme, catalytic polypeptide-like) activity (SI2 and SI13), mismatch repair (MMR) and aging (SI6/SI15 and SI1/SI5), and ultraviolet (UV) radiation exposure (SI7) (Figure 2 ) (eFigure 2 in Supplement 1). 38 The smoking-related signature SI4 was enriched for cytosine (C)>adenine (A) transversions and strongly associated with smoking status in lung adenocarcinoma (P =9.1×10 −15 ) ( Figure 2 ) and to a lesser extent in lung squamous cell carcinoma (P = .08). No signatures were associated with ancestry, suggesting that the mutagenic processes are similar in lung tumors from black and white populations in lung adenocarcinoma or lung squamous cell carcinoma (P >.05for all) (eFigure 3 in Supplement 1).
Lack of Association Between Genomic Alterations and Ancestry
To assess the relationship between ancestry and mutation status, we examined the mutational frequencies in 313 lung adenocarcinomas and 138 lung squamous cell carcinomas. This set excluded 6 adenocarcinomas and 4 squamous cell carcinomas from patients whose ancestry was not confirmed on PC1 or were outliers on PC2 in the PCA analysis ( Figure 1 ). Clinical variables were not significantly associated with ancestry in either set of tumors with the exception of smoking packyears (P < .05 for all) (eTables 3 and 4 in Supplement 2). The total number of putative somatic mutations, the percentage of genes amplified, or the percentage of genes deleted per tumor were not associated with ancestry (eFigure 4 in Supplement 1). Similarly, other quality control metrics were not associated with ancestry (eFigure 4 in Supplement 1). When examining previously characterized cancer genes in lung adenocarcinoma, the most commonly mutated oncogenes included KRAS (34%), EGFR (14%), and BRAF (7%), while the most commonly mutated tumor suppressors included TP53 (60%), STK11 (14%), and ARID1A (9%) (Figure 3) . The most commonly mutated lung squamous cell carcinoma oncogenes included NFE2L2 (12%), and PIK3CA (9%) while tumor suppressors included TP53 (88%), CDKN2A (17%), and PTEN (14%) (eFigure 5 in Supplement 1). Using the Fisher exact test, we did not observe any statistical association between ancestry and mutation frequencies for any gene after correction for multiple hypothesis testing in either tumor type (FDR Q > .05) (eTables 5 and6inSupplement 2). We also compared the mutational frequencies in this cohort with the mutational frequencies found in tumors from TCGA and related studies. 15 In lung adenocarcinoma, TP53 had a higher mutation frequency in tumors from black patients (P = .02), NF1 had a lower mutation frequency in tumors from white patients (P = .045), and KEAP1 had lower mutational frequencies in tumors from both populations (P < .001) in this cohort compared with tumors from TCGA (n = 660) ( Figure 3 ). No significant differences were observed between the lung squamous cell carcinomas from this cohort and those from TCGA (n = 484) using the Fisher exact test (P > .05 for all) (eFigure5inSupplement 1).
We also determined if the number of copy number gains or losses for individual genes was significantly different between populations in either tumor type. Similar to the mutational profiles, we did not observe significant differences after correction for multiple hypothesis testing for the majority of genes (eFigures 6 and 7 in Supplement 1; eTables 7-10 in Supplement 2). The only exception is SULT1A1, which displayed a modestly significantly higher number of gains in tumors from black patients (FDR Q = .06). Finally, while the We identified single-nucleotide variations (SNVs) that were likely to be germline (ie, inherited and not acquired) due to their presence in African American or non-Finnish European (NFE) populations at a frequency of at least 1%. We performed principal component analysis (PCA) on these SNVs (n = 3517) and found that principal component 1 (PC1) was strongly correlated with self-reported race (P =7 .6×10 −79 ). Two reported white patients strongly clustered with the black population, and 6 reported black patients strongly clustered with the white population. The misclustering of these patients could be due to errors in clinical data collection or differences in the patient's self-perceived race from their biological ancestry. The samples from these patients were excluded from further analyses examining the relationship between ancestry and genomic alterations.
numbers were too small for statistical evaluation in lung adenocarcinoma, we observed one ALK rearrangement and one ROS1 rearrangement in tumors from black patients ( Figure 3 ) (eTable 11 in Supplement 2). Two RET rearrangements were observed in tumors from white patients.
Ras/Raf/RTK Pathway Alterations in Lung Adenocarcinomas From Black Patients
In lung adenocarcinoma, alterations in members of the Ras/ Raf/RTK signaling pathways are of particular interest because they confer sensitivity to clinically approved targeted therapeutics. 39 We first examined the mutational profile of EGFR and observed 46 mutations across 41 tumors ( Figure 4A ). Five tumors had more than one EGFR mutation including p.V769M/p.ELREA746del, p.S768I/p.V769L, p.V769M/ p.L858R, p.T790M/p.L858R, and p.G719A/p.L861Q. In-frame indels in exon 19 were observed in both men and women and did not show enrichment in black vs white women as has been previously reported 23 (Fisher exact P = .80). The overall frequency of activating EGFR mutations was not associated with ACT  CCA  CCC  CCG  CCT  GCA  GCC  GCG  GCT  TCA  TCC  TCG  TCT  ACA  ACC  ACG  ACT  CCA  CCC  CCG  CCT  GCA  GCC  GCG  GCT  TCA  TCC  TCG  TCT  ACA  ACC  ACG  ACT  CCA  CCC  CCG  CCT  GCA  GCC  GCG  GCT  TCA  TCC  TCG  TCT  ATA  AT C  AT G  AT T  CTA  CTC  CTG  CTT  GTA  GTC  GTG  GTT  TTA  TTC  TTG  TTT  ATA  AT C  AT G  AT T  CTA  CTC  CTG  CTT  GTA  GTC  GTG  GTT  TTA  TTC  TTG  TTT  ATA  AT C  AT G  AT T  CTA  CTC  CTG  CTT  GTA  GTC  GTG  GTT  TTA  TTC  TTG 
Lung adenocarcinoma
Lung squamous cell carcinoma A, Four mutational signatures were identified using nonnegative matrix factorization on 96 trinucleotide mutation types across 509 lung tumors including those related to smoke exposure (SI4), aberrant APOBEC activation (SI13 and SI2), aging (and SI1/5) and mismatch repair (SI15/6), and UV exposure (SI7). Each bar corresponds to the probability of observing a particular mutation in a trinucleotide context within each signature. B, The smoking signature was associated with smoking status in lung adenocarcinoma (P =9 . 1×10
−15
) and to a lesser extent lung squamous cell carcinomas (P = .08). MMR indicates mismatch repair.
Lung Cancer Mutations Among Black and White Populations
Original Investigation Research jamaoncology.com (Reprinted) JAMA Oncology June 2017 Volume 3, Number 6 805 ancestry (P = .51) ( Figure 4B ). Using lung adenocarcinomas from patients with sufficient clinical annotation (n = 303), we performed logistic regression examining EGFR mutation status as a function of ancestry, sex, and smoking status. A significant increase was observed in never-smokers compared with ever-smokers (P =2.85×10 −6
), and a modest increase in females compared with males (P = .08). However, no significant association was observed between EGFR mutation status and ancestry (P = .35) (eFigure 8 in Supplement 1 and eTable 12 in Supplement 2).
To determine if the overall frequency of mutations from any gene in the pathway was associated with race, we designated lung adenocarcinomas that had a previously characterized activating somatic single-nucleotide variants, indel, amplification, or gene fusion in a known RTK/Ras/Raf driver 13, 40, 41 as "oncogene positive" (n = 128) while the remaining lung adenocarcinomas were considered "oncogene negative" (n = 185). Only fusions with canonical breakpoints were considered. MET and ERBB2 were considered amplified if the tumor had a log2 copy number ratio greater than 1.
15 Ancestry was not significantly associated with oncogene negative status using a Fisher exact test (P = .36) ( Figure 4B ). This lack of association was also observed in a logistic regression model controlling for smoking status and sex (P = .36) (eFigure 8 in Supplement 1 and eTable 13 in Supplement 2). These results indicate that the proportions of Ras/Raf/RTK pathway alterations are similar between lung cancer patients from black and white populations in this study population.
Discussion
The primary goal of this study was to determine if the frequencies of putative acquired alterations in lung tumors are different between black and white ancestries. We examined variants in 504 genes from 313 lung adenocarcinomas and 138 lung squamous cell carcinomas and did not observe associations between ancestry and somatic genomic alterations within each histological subtype. As the targeted sequencing panel used in this study was limited to cancer genes, we did not have the ability to perform comprehensive ancestral inference and classification. However, we were able to capture SNVs in the cancer genes likely to be inherited due to their relatively high frequency in nondisease tissue from the Exome Aggregation Consortium database. We observed that the variation among these markers was strongly associated with self-reported race and largely confirmed the status of the self-reported race annotation in the majority of cases. The misclustering of tumors from 8 patients could be owing to errors in clinical data collection or differences in the patient's self-identified race from their biological ancestry.
We We examined previously characterized activating mutations in genes that are members of the Ras/Raf/RTK pathway. 13,15 A, A total of 23 activating single-nucleotide variations (SNVs) and 23 in-frame indels were found in EGFR across 313 lung adenocarcinomas. These mutations are grouped by smoking status, sex, and ancestry. One EGFR p.L858R mutation in tumor from a white female is not shown in this figure due to lack of smoking annotation. B, We did not observe a significant enrichment or depletion of known activating mutations in EGFR (left) or all activating mutations in the pathway (right) between tumors from black and white populations (P > .05 for all).
Lung Cancer Mutations Among Black and White Populations
Original well as EGFR and ERBB2 indels and ALK translocations. They did not find any significant differences in individual genes, but did observe an overall reduction in the frequency of tumors from black patients that had any driver alteration (P = .04). Due to the exploratory nature of these studies, no correction for multiple hypothesis testing was performed. However, foregoing this correction increases the risk of observing false positives due to chance and reduces the likelihood of replication in future studies. This may be a contributing factor in our inability to replicate the findings from these studies. Our cohort of lung cancers was collected from institutions in the same region and clinical setting, profiled with the same DNA sequencing assay and was well matched for clinical variables with the exception of pack-years of smoking. Although the value of pack-years was associated with ancestry, we did not observe significant differences in the smokingassociated signature (SI4) suggesting that differences between the populations in smoke exposure are minimal in our cohort. While this study profiled the largest number of genes compared with any of the previous studies, we cannot rule out the possibility that another gene outside of our assayed regions will have substantially different mutational frequencies between black and white populations. However, since the previously characterized recurrently altered genes in both tumor types 12,13,15 did not display significant differences, we believe that the possibility of another gene displaying strong differences between populations is unlikely. We did observe a modest increase in the proportion of tumors with copy number gains in SULT1A1 from black patients. However, the variability in this region is likely germline as previously reported.
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Limitations
The mutational frequencies in this cohort were not significantly different from those observed in TCGA cohorts for most genes suggesting that the tumors in our cohort are not substantially different from those in TCGA. The only exceptions were in lung adenocarcinoma and included the tumor suppressors TP53, NF1, and KEAP1. Because we did not have access to paired normal tissue, we limited the missense and splice site mutations in our analysis to those previously observed in human cancers as annotated in the COSMIC (Catalogue Of Somatic Mutations In Cancer) database. This may have led to the exclusion of some true novel somatic mutations and contributed to the lower mutational frequencies observed in these genes.
Conclusions
In addition to the mutational frequencies of individual genes, we examined the differences in the frequency of previously curated Ras/Raf/RTK pathway alterations known to drive cellular transformation in lung adenocarcinoma. We again did not observe significant associations between ancestry and the mutational frequencies of the pathway members included in this panel. Therefore, we believe that clinical sequencing coupled with targeted therapies against these alterations will benefit patients in both populations. Overall, these results suggest that differences in exomic mutations do not contribute to the observed racial disparities in incidence and mortality between black and white populations. Further investigation into other genomic factors such as mutations in noncoding regions, epigenetic alterations, and gene expression changes or other socioeconomic variables beyond smoking behavior and access to health care may be required to fully explain these disparities.
eMethods
Additional cohort information Independent pathological assessment was performed by a board certified Anatomic Pathologist with thoracic pathology expertise in the Department of Pathology, Brigham and Women's Hospital. Never smokers were defined as adults who had smoked less than 100 cigarettes in their lifetime. A former smoker was defined as an adult who had smoked at least 100 cigarettes in his or her lifetime but who had quit smoking at the time of interview.
Hybrid capture and sequencing of cancer genes DNA was extracted and sonicated to 250 bp following Covaris FFPE DNA Extraction & Purification protocol and further purified using Agencourt AMPure XP beads. Libraries were made with sample specific barcodes, quantified using qPCR, and the libraries were pooled in equimolar concentrations to a total of 500 ng for OncoPanel enrichment (Agilent SureSelect) for hybrid capture of 502 cancer related genes. Libraries were sequenced on an Illumina HiSeq2500 to a mean depth of coverage of 208X (range 0.50 682X). Tumors with >30X sequencing depth over >80% of targeted bases were analyzed.
Alignment
Pooled sample reads were de multiplexed and sorted using Picard (http://broadinstitute.github.io/picard/command line overview.html). Reads were aligned to the reference sequence b37 edition from the Human Genome Reference Consortium using BWA using the following parameters " q 5 l 32 k 2 o 1". Duplicate reads were marked using Picard tools. The Genome Analysis Tool Kit (GATK2) was used for local realignment of reads around indels and base quality score recalibration (BQSR).
Mutation calling
MuTect and SomaticIndelDetector (http://www.broadinstitute.org/cancer/cga/indelocator) were used to identify somatic single nucleotide variants (SNVs) and short insertions or deletions (indels), respectively. Mutation annotation was performed using Oncotator.
Copy number and rearrangements calling
Copy number alterations were called using ReCapSeg (http://gatkforums.broadinstitute.org/categories/cancer tools) using default parameters. ReCapSeg performs tangent normalization against a "panel of normals" to remove systematic noise and technical artifacts. We used a panel of 49 samples from normal tissue and three normal cells lines profiled with the same OncoPanel platform.
Rearrangements were detected using BreaKmer (https://github.com/ccgd profile/BreaKmer) and confirmed by manual review of sequences.
Inference of mutational signatures
Non negative matrix factorization (NMF) was used to deconvolute a M x N matrix of mutation catalogues into a M x K matrix of mutational processes and an K x N matrix of mutational exposures (where N is the number of tumors, M is the number of mutation types, and K is the number of estimated mutational processes). Code to run NMF was obtained from http://www.mathworks.com/matlabcentral/fileexchange/38724 and run using the nnmf function from the MATLAB Statistics Toolbox. We used 6 mutation types with 16 different trinucleotide contexts for a total of 96 mutational states. The number of possible signatures was varied from 1 to 10 and signature stability was assessed via sampling as previously described [ref] . The cosine correlation was used to determine similarity between signatures derived in this dataset and signatures from the COSMIC database.
Principle Component Analysis
For the PCA analysis, we used 3,517 SNV sites called by MuTect that were found in more than 1% of African American or European populations in the ExAC database. Variants with an alternate allele fraction less than 0.95 were considered heterozygous while variants with an alternate allele fraction greater than 0.95 were considered homozygous for the alternate allele. Let be the matrix of variants with SNV and tumor , where and . Each entry in the matrix was coded as 0, 1, or 2 corresponding to homozygous or for the reference, heterozygous, or homozygous for the alternate allele, respectively. Each SNV was centered and scaled according to equation 1: (Eq. 1) where and . PCA was performed on the scaled matrix using the prcomp function in the R statistical computing language.
Statistical analysis
For each gene, the Fisher's exact test was used to compare the frequency of mutated tumors between populations. Genes mutated in five or fewer tumors were not considered. Nonparametric tests such as the Wilcoxon rank sum test (comparison between 2 groups) or the Kruskal Wallis test (comparison between more than two groups) were used for continuous variables. Correction for multiple hypothesis testing was performed with the Benjamini Hochberg procedure.
Study power
Power calculations for the Fisher's exact test were performed using 50,000 simulations with the "power.fisher.test" function in the "statmod" R package. In this study, the lung adenocarcinoma cohort had 87% power to detect a gene mutated in 1% percent in tumors from white patients and 10% in tumors from black patients at a significance level of 0.01. The lung squamous cell carcinoma cohort had 32% power using the same parameters. eFigures eFigure 1. Flow chart of variant filtering procedure. As matched normal DNA was not available for these patients, we applied several criteria to limit the influence of inherited (i.e. germline) variants in the analysis. First, we excluded variants found in the Exome Aggregation Consortium (ExAC, version 3, http://exac.broadinstitute.org/) in a frequency greater than 0.0005 in the African American (AA) or Non Finnish European (NFE) populations. Multi allelic variants in ExAC were decomposed and normalized with vt (https://github.com/atks/vt) before matching with variants from this cohort. Second, we excluded variants outside of coding exons such as those in flanking regions, UTRs, and introns. For mutational signature inference, variants with alternate allele fractions between 0.4 and 0.6 or that did not have an annotated transcript strand were excluded. For analyses examining the association between clinical phenotypes and mutation status, missense, splice site, and nonsense SNVs were limited to variants previously observed in tumors as described in the Catalogue of Somatic Mutations in Cancer (COSMIC) database v74. Additional variants excluded after manual review included those in MUC2 (chr11:1092891C>A and chr11:1093204C>A) and in MSN (chrX:64956743A>G and chrX:64956699_G>A). eFigure 2. Correlation between mutational signatures derived in this cohort and previously defined signatures from COSMIC. The trinucleotide probabilities for 30 signatures generated from 10,952 exomes and 1,048 whole genomes across 40 were obtained from COSMIC (http://cancer.sanger.ac.uk/cancergenome/assets/signatures_probabilities.txt). A pair wise cosine correlation was performed between all COSMIC signatures and signatures from this study. The top correlated COSMIC signatures were used determine the identity of each signature in this cohort and each signature was renamed accordingly. EGFR activating mutation frequency Ras/Raf/RTK activating mutation frequeny
